Phencyclidine-Like Abuse Liability and Psychosis-Like Neurocognitive Effects of Novel Arylcyclohexylamine Drugs of Abuse in Rodents.

Saved in:
Bibliographic Details
Title: Phencyclidine-Like Abuse Liability and Psychosis-Like Neurocognitive Effects of Novel Arylcyclohexylamine Drugs of Abuse in Rodents.
Authors: Shaw HE; Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas (H.E.S., D.R.P., B.M.G., L.R.F., W.E.F.); Drug Enforcement Administration, United States Department of Justice, Washington, DC (T.M.C.); and Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland (C.R.J.)., Patel DR; Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas (H.E.S., D.R.P., B.M.G., L.R.F., W.E.F.); Drug Enforcement Administration, United States Department of Justice, Washington, DC (T.M.C.); and Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland (C.R.J.)., Gannon BM; Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas (H.E.S., D.R.P., B.M.G., L.R.F., W.E.F.); Drug Enforcement Administration, United States Department of Justice, Washington, DC (T.M.C.); and Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland (C.R.J.)., Fitzgerald LR; Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas (H.E.S., D.R.P., B.M.G., L.R.F., W.E.F.); Drug Enforcement Administration, United States Department of Justice, Washington, DC (T.M.C.); and Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland (C.R.J.)., Carbonaro TM; Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas (H.E.S., D.R.P., B.M.G., L.R.F., W.E.F.); Drug Enforcement Administration, United States Department of Justice, Washington, DC (T.M.C.); and Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland (C.R.J.)., Johnson CR; Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas (H.E.S., D.R.P., B.M.G., L.R.F., W.E.F.); Drug Enforcement Administration, United States Department of Justice, Washington, DC (T.M.C.); and Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland (C.R.J.)., Fantegrossi WE; Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas (H.E.S., D.R.P., B.M.G., L.R.F., W.E.F.); Drug Enforcement Administration, United States Department of Justice, Washington, DC (T.M.C.); and Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland (C.R.J.) WEFantegrossi@uams.edu.
Source: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2024 Jun 21; Vol. 390 (1), pp. 14-28. Date of Electronic Publication: 2024 Jun 21.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0376362 Publication Model: Electronic Cited Medium: Internet ISSN: 1521-0103 (Electronic) Linking ISSN: 00223565 NLM ISO Abbreviation: J Pharmacol Exp Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1521-0103
DOI:10.1124/jpet.123.001942